This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
HCA Healthcare's (HCA) Q4 Earnings Beat on Improved Admissions
by Zacks Equity Research
HCA Healthcare (HCA) expects EPS in the range of $19.70-$21.20 for 2024, the midpoint being 7.6% higher than the 2023 figure.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
HealthEquity, Inc. (HQY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
HealthEquity (HQY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.26% and 1.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Elevance Health (ELV) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Elevance Health (ELV) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
ELV or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. HQY: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Why You Should Retain Elevance (ELV) Stock in Your Portfolio
by Zacks Equity Research
Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.
Why Elevance Health (ELV) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Elevance Health (ELV) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Elevance Health (ELV) stood at $475.12, denoting a -1.49% change from the preceding trading day.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
by Zacks Equity Research
Elevance Health (ELV) launches a new program with an Affordable Connectivity Program offering free smartphones to eligible members.
Elevance Health (ELV) Enhances Whole Health With Paragon Buyout
by Zacks Equity Research
Elevance Health (ELV) agrees to acquire Paragon Healthcare, boosting its capabilities in specialty pharmacy.
Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?
by Zacks Equity Research
Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Centene (CNC) Stock For Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.
The Zacks Analyst Blog Highlights Medpace, Elevance Health and HealthEquity
by Zacks Equity Research
Medpace, Elevance Health and HealthEquity are part of the Zacks top Analyst Blog
3 Amazing Health Service Stocks to Brave "Labordemic" in 2024
by Urmimala Biswas
Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Elevance Health (ELV) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Elevance Health (ELV) concluded the recent trading session at $465.78, signifying a -0.76% move from its prior day's close.
Cigna's (CI) Medicare Advantage Unit Draws Acquisition Interest
by Zacks Equity Research
The final bids for Cigna's (CI) Medicare Advantage unit are expected next week.